Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Daewoong Pharmaceutical
Daewoong Pharmaceutical
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
Therapeutic: ensifentrine for chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) comes in various guises, including chronic bronchitis and emphysema; and, although incurable, the symptoms can be managed with...
Merck’s clesrovimab meets all primary endpoints in Phase IIb/III trial for RSV in infants
A teaser of the Phase IIb/III trial released by Merck indicates that clesrovimab can reduce the need to medically attend lower respiratory infections caused by RSV in infants
Bringing biotech to the Baltics: the rise of Lithuania
Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a...
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Research & Development
AffyXell expands partnership with GenScript ProBio
As part of the strategic alliance, GenScript has committed to take an equity position in AffyXell at a future funding round
Ingredients
Avacta expands South Korean partnership to include COVID-19 neutralising therapy
Avacta Group has expanded its collaboration and license agreement with Daewoong Pharmaceutical and AffyXell Therapeutics
Ingredients
Affibody announces diabetes option exercise by Daewoong
Affibody will receive a license conversion fee and milestone payments as well as royalties. Further financial details were not disclosed.
Ingredients
Avacta, Daewoong and AffyXell to work on proteins for a range of targets
AffyCell has agreed to provide funds to Avacta for R&D costs of proteins produced by mesenchymal stem cells
Research & Development
Daewoong Pharmaceutical opens Chinese laboratory
Now established in Beijing and Shenyang
Subscribe now